Vor Biopharma Inc. (VOR) Balance Sheet

The company's accumulated deficit has grown from $370.9M in 2024Q1 to $1.4B in 2026Q2, reflecting sustained R&D investment without revenue. The shift to negative equity in 2025Q3, when total liabilities ballooned to $2.4B, appears tied to a one-time non-cash charge, but the trend underscores a structurally capital-intensive model. Investors should monitor whether future financing rounds can restore positive equity without excessive dilution.

The company appears to have repaid or converted its debt, as total debt fell from $34.7M in 2024Q1 to $2.9M by 2026Q2, with no debt in 2025Q2. However, the negative equity base means leverage metrics are distorted; the real risk lies in future financing needs, as the cash runway is finite. The absence of significant debt may indicate reliance on equity markets, which could be dilutive in a challenging biotech funding environment.

The company's total assets of $481.1M are primarily liquid, with negligible goodwill and minimal fixed assets, consistent with a virtual biotech model that relies on external partners for manufacturing. This asset-light structure reduces capital intensity but increases dependence on third-party capabilities, which could introduce supply chain risks. The sharp decline in PPE from $48M in 2024Q1 to $3.4M suggests a strategic shift away from internal facilities, possibly to conserve cash.

The company has raised substantial capital, but operating losses have outpaced funding, leading to a negative equity position. This is common for clinical-stage biotechs, but the magnitude of the deficit suggests that future financing will be heavily dilutive. The $1.7B gain in 2025Q4, likely from a change in fair value of warrants or similar, temporarily boosted equity, but the underlying trend remains one of capital consumption. Investors should monitor the pace of cash burn relative to clinical milestones.

The sharp drop in cash suggests significant operating burn, with quarterly cash consumption likely exceeding $100M in recent periods, despite the high current ratio. The current ratio is inflated by low current liabilities, but the absolute cash level is more critical for a pre-revenue company. Based on prior cash flow analysis, the company may have less than one year of runway at current burn rates, unless additional financing is secured or spending is curtailed.